Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MicuRx Pharmaceuticals has nominated MRX-I, an antibacterial molecule targeting multi-drug resistant gram-positive bacteria, including methicillin-resistant Staphylococcus aureus, as its first preclinical development candidate.
Subscribe to our email newsletter
Simultaneously, the company expanded its operations in China to increase MicuRx’s capacity in antibacterial drug discovery and development.
To facilitate the development of its lead compounds and expand the research capacity, MicuRx recently moved its R&D operations in China to a new 10,000sqft facility in the ZhangJian HighTech Park in Shanghai, China.
The company intends to use this integrated chemistry and biology facility for drug discovery and development activities to advance its next-generation antimicrobial products.
Zhengyu Yuan, president and CEO of MicuRx Pharmaceuticals, said: “Only 12 months after initial funding, we have discovered multiple drug leads and selected our first development candidate MRX-I, a promising antibacterial compound that we expect to be superior to many of the top-selling antibiotics available today.
“This enhanced productivity is owed in part to our hybrid business model that leverages the drug discovery capacity readily available in China and the superior management expertise in the US.”